Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial.
about
Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseasesThe approval process for biosimilar erythropoiesis-stimulating agentsUpdate on the safety and bioequivalence of biosimilars - focus on enoxaparin.The evolving role of biosimilars in haematology-oncology: a practical perspective.Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575.Quantitative assessment of minimal effective concentration of erythropoiesis-stimulating agents.Clinical trials for authorized biosimilars in the European Union: a systematic review.Biosimilar recombinant human erythropoietins ("epoetins") and future erythropoiesis-stimulating treatments.Clinical safety of biosimilar recombinant human erythropoietins.Epoetin biosimilars in Europe: five years on.Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease.State-of-the-art biosimilar erythropoietins in the management of renal anemia: lessons learned from Europe and implications for US nephrologists.Use of biosimilar epoetin to increase hemoglobin levels in patients with chemotherapy-induced anemia: real-life clinical experience.Pharmacokinetic similarity of biologics: analysis using nonlinear mixed-effects modeling.Comparison of the pharmacokinetic and pharmacodynamic profiles of one US-marketed and two European-marketed epoetin alfas: a randomized prospective study.A pharmacoepidemiological study of the multi-level determinants, predictors, and clinical outcomes of biosimilar epoetin alfa for renal anaemia in haemodialysis patients: background and methodology of the MONITOR-CKD5 study.Safety Evaluation of Lipid Nanoparticle-Formulated Modified mRNA in the Sprague-Dawley Rat and Cynomolgus Monkey.HX575: established biosimilarity in the treatment of renal anemia and 10 years of clinical experience.Effectiveness of Switch to Erythropoiesis-Stimulating Agent (ESA) Biosimilars versus Maintenance of ESA Originators in the Real-Life Setting: Matched-Control Study in Hemodialysis Patients.Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?Development and 10-year history of a biosimilar: the example of Binocrit®.
P2860
Q27013577-4D7FC80C-D61A-409E-A969-325046112DDEQ34124734-DFAAEAB6-8645-44F6-9E62-6D3FE5406FECQ34352446-08362314-A93E-458C-9505-E4BCBB20C7E1Q36291259-84C7A418-494C-473D-B657-ABBE1F0D6C35Q36354544-1EDCADEE-6A8E-476B-A6EB-D98C6AD54734Q37308372-A7A57BE1-CFE0-42C6-AF0C-0831DE140601Q37399588-44932722-7C09-4B75-84A7-ED051FEF9FBBQ37999380-BBCBECD4-1176-40F7-A1C5-9F59786755F8Q38033576-881DBD85-304C-4647-A14A-B67BA371444BQ38067654-5016323C-95AD-4860-A6BB-13DCC73CCEC3Q38075798-1676D49C-56E2-4A91-B301-8C987117BD4AQ38556990-E0FBD851-ABF4-406B-BDF2-7B7AE78A5F07Q39637230-DCB81009-0702-4CFE-9E20-0F907164E009Q41998537-6D576648-8EC2-47D2-AE26-5AD3CE99496BQ43237097-0BED039F-D98B-4CD1-AD42-4D4DE8B85F8FQ44463941-63CAF402-C4AC-442C-AB94-FCB8217DF715Q46250879-A2C18345-2DD6-417D-9EB7-C08700A1F551Q47094186-5174D19E-2FC3-4F3C-8F05-B1E34333746BQ48287588-E2F35791-E052-4152-B584-47C5A58420BAQ54959955-2FD7F021-8C40-45D7-8CD6-6DB571B345E2Q55177169-829F017D-CE5F-4248-A5B8-859E4735006F
P2860
Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Bioequivalence of HX575 (recom ...... l randomised controlled trial.
@ast
Bioequivalence of HX575 (recom ...... l randomised controlled trial.
@en
type
label
Bioequivalence of HX575 (recom ...... l randomised controlled trial.
@ast
Bioequivalence of HX575 (recom ...... l randomised controlled trial.
@en
prefLabel
Bioequivalence of HX575 (recom ...... l randomised controlled trial.
@ast
Bioequivalence of HX575 (recom ...... l randomised controlled trial.
@en
P2093
P2860
P356
P1476
Bioequivalence of HX575 (recom ...... l randomised controlled trial.
@en
P2093
Andrea Vetter
Bernhard Vens-Cappell
Fritz Sörgel
Martina Kinzig
Ursula Thyroff-Friesinger
P2860
P2888
P356
10.1186/1472-6904-9-10
P577
2009-05-22T00:00:00Z
P5875
P6179
1030018810